NCT00710580

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 350 (actual)
• Sponsor: AbbVie (prior sponsor, Abbott) · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Compare the efficacy of ABT-874 versus etanercept in subjects with moderate to severe plaque psoriasis

Conditions

• Moderate to Severe Plaque Psoriasis

Interventions

Type	Name	Description
BIOLOGICAL	ABT-874	SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
BIOLOGICAL	etanercept	SQ injection 50 mg BIW
DRUG	placebo	SQ placebo injections for ABT-874 and etanercept

Timeline

• Start date: 2008-07-01
• Primary completion: 2009-04-01
• Completion: 2009-04-01
• First posted: 2008-07-04
• Last updated: 2013-01-18

Locations

42 sites across 1 country: United States